Endocrine side effects of broad-acting kinase inhibitors
Authors:
Open Access
- 1 September 2010
- journal article
- review article
- Published by Bioscientifica in Endocrine-Related Cancer
- Vol. 17 (3) , R233-R244
Abstract
Targeted therapy in oncology consists of drugs that specifically interfere with abnormal signaling pathways that are dysregulated in cancer cells. Tyrosine kinase inhibitors (TKIs) take advantage of unique oncogenes that are activated in certain types of cancer, and also target common mechanisms of growth, invasion, metastasis, and angiogenesis. However, many kinase inhibitors for cancer therapy are somewhat nonselective, and most have additional mechanisms of action at the cellular level, which are not completely understood. The use of these agents has increased our knowledge of important side effects, of which the practicing clinician must be aware. Recently, proposed endocrine-related side effects of these agents include alterations in thyroid function, bone metabolism, linear growth, gonadal function, fetal development, and glucose metabolism, and adrenal function. This review summarizes the most recent data on the endocrine side effects of TKIs.Keywords
This publication has 85 references indexed in Scilit:
- Phase II Trial of Sorafenib in Metastatic Thyroid CancerJournal of Clinical Oncology, 2009
- Growth deceleration in a girl treated with imatinibInternational Journal of Hematology, 2009
- Targeting cancer with small molecule kinase inhibitorsNature Reviews Cancer, 2009
- Nilotinib: A second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemiaClinical Therapeutics, 2008
- Blood glucose levels in patients with metastatic renal cell carcinoma treated with sunitinibBritish Journal of Cancer, 2008
- Gynecomastia in a male after dasatinib treatment for chronic myeloid leukemiaLeukemia, 2008
- Hypopituitarism following radiotherapyPituitary, 2008
- Imatinib and Regression of Type 2 DiabetesNew England Journal of Medicine, 2005
- Imatinib Mesylate May Improve Fasting Blood Glucose in Diabetic Ph+ Chronic Myelogenous Leukemia Patients Responsive to TreatmentJournal of Clinical Oncology, 2004
- VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formationNature Medicine, 1999